Y-27632 dihydrochloride: Selective ROCK Inhibitor for Precision Cytoskeletal Modulation

Executive Summary: Y-27632 dihydrochloride is a small-molecule inhibitor that targets ROCK1 and ROCK2 with nanomolar potency and over 200-fold selectivity versus unrelated kinases (ApexBio). It disrupts Rho-mediated cytoskeletal rearrangements, modulates cell cycle progression, and impairs cytokinesis in vitro and in vivo (Peptide17). Y-27632 enhances stem cell viability and suppresses tumor cell invasion and metastasis in animal models (5-Methoxy-CTP). The compound is highly soluble in DMSO, ethanol, and water, with stability parameters well characterized. Its use as a benchmark in cell signaling and regenerative medicine is supported by reproducible, quantitative data across diverse systems.

Biological Rationale

ROCK1 and ROCK2 are serine/threonine kinases central to the Rho/ROCK signaling pathway, regulating actin cytoskeleton organization, cell contractility, migration, and division (Mishra et al., 2024). Dysregulation of Rho/ROCK signaling contributes to pathological processes including tumor invasion, metastasis, fibrosis, and neurodegeneration. Selective inhibition of ROCK kinases enables precise dissection of these pathways without off-target effects on kinases such as PKC or MLCK. In stem cell biology, ROCK inhibition enhances cell survival during dissociation and passaging, a process reliant on cytoskeletal remodeling (LH-RH Acetate Salt). Y-27632 dihydrochloride has become the reference compound for these applications due to its potency, specificity, and reproducibility.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a cell-permeable pyridine derivative that competitively inhibits the ATP-binding sites of ROCK1 (IC₅₀ ≈ 140 nM) and ROCK2 (K_i ≈ 300 nM) (ApexBio). This inhibition blocks the phosphorylation of downstream substrates including myosin light chain (MLC), LIM kinase, and cofilin, leading to disassembly of actin stress fibers and focal adhesions. By interfering with Rho-mediated contractility, Y-27632 suppresses formation of actin-myosin bundles critical for cell shape, migration, and division. Inhibition of ROCK signaling also modulates cell cycle transition from G1 to S phase and disrupts cytokinesis, resulting in altered proliferation profiles (Peptide17). The compound does not significantly inhibit unrelated kinases at concentrations up to 30 μM, confirming its selectivity. This mechanism underlies its utility as a tool compound in both fundamental and translational research.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a K_i of ~300 nM, demonstrating over 200-fold selectivity against kinases such as PKC, cAMP-dependent PKA, MLCK, and PAK (ApexBio).
• In human-induced pluripotent stem cell (hiPSC) cultures, Y-27632 increases post-dissociation cell survival by >4-fold compared to untreated controls, supporting its use in regenerative medicine workflows (5-Methoxy-CTP).
• In vitro, Y-27632 reduces prostatic smooth muscle cell proliferation in a concentration-dependent manner, with significant effects observed at 10 μM for 48 hours (ApexBio technical data).
• In vivo, Y-27632 administration reduces tumor invasion and metastasis in mouse xenograft models of cancer (Peptide17).
• Y-27632 is highly soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water; solubility can be increased with mild heating or sonication (ApexBio product sheet).
• Stock solutions remain stable below -20°C for several months, but long-term storage after dilution is not recommended (ApexBio).
• Y-27632 does not significantly inhibit unrelated kinases at concentrations up to 30 μM, as shown by kinase panel profiling (ApexBio).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is validated for use in cell biology, cancer research, and regenerative medicine. It is employed to:

• Dissect the Rho/ROCK signaling pathway in mechanistic studies.
• Enhance survival of dissociated stem cells and primary cells (contrasting LH-RH Acetate Salt: This article provides updated benchmarks and troubleshooting not covered in basic protocols.).
• Suppress tumor cell invasion and metastasis in preclinical cancer models.
• Study cytoskeletal dynamics, cell cycle progression, and cytokinesis.
• Model neurodegenerative pathways where Rho/ROCK signaling is implicated (Mishra et al., 2024).

Common Pitfalls or Misconceptions

• Not a universal cell survival factor: Y-27632 is most effective for stem/progenitor cells; effects in terminally differentiated cell types vary by context.
• ROCK-independent effects are rare: At standard concentrations (≤10 μM), off-target kinase inhibition is negligible; higher concentrations may yield non-ROCK effects.
• Does not reverse all forms of apoptosis: Y-27632 does not rescue cells from apoptosis induced by DNA damage or oxidative stress unrelated to cytoskeletal tension.
• Not suitable for chronic systemic administration: In vivo, prolonged ROCK inhibition may cause vascular and systemic side effects; most studies use short-term or local administration (see L3400: This article expands on translational risks and strategic use cases.).
• Solubility is temperature dependent: Full dissolution may require mild heating or sonication; improper solubilization can lead to inconsistent dosing (IBUPR: Here, the focus is on optimizing intestinal stem cell workflows—this article generalizes best practices for all cell types.).

Workflow Integration & Parameters

For in vitro experiments, Y-27632 dihydrochloride is typically reconstituted in DMSO at ≥111.2 mg/mL and diluted to final working concentrations of 1–10 μM. Solubility in ethanol (≥17.57 mg/mL) and water (≥52.9 mg/mL) enables flexibility for specific assay requirements. Warming to 37°C or brief sonication enhances dissolution. Solutions should be stored desiccated at 4°C or below, with aliquots for long-term storage at -20°C. Avoid repeated freeze-thaw cycles and extended storage of working solutions. In stem cell workflows, Y-27632 is added immediately after cell dissociation and removed after 24–48 hours to promote recovery and attachment. For cancer and cytoskeletal studies, dosing regimens should be titrated based on cell type and endpoint. When integrating into multi-kinase inhibitor panels, confirm that total DMSO concentration remains below cytotoxic thresholds (typically <0.1%).

Conclusion & Outlook

Y-27632 dihydrochloride is a benchmark selective ROCK inhibitor, enabling precise manipulation of cytoskeletal dynamics, cell proliferation, and invasion. Its potency, selectivity, and established protocols make it an indispensable reagent for studies of Rho/ROCK signaling and translational applications in regenerative medicine and cancer biology. For detailed protocols, troubleshooting, and product specifications, refer to the A3008 product page. As research advances, continued benchmarking and cross-laboratory validation will further clarify its applicability and boundary conditions.